CD8A and neoplasm: Collectively, the functional state and antigen-specificity are the two key determinants of the anti-tumor capacity of CD8+ T cells; and the combination of scRNA-seq and scTCR repertoire analyses enables efficient identification and lineage tracing of tumor-reactive T cells within the human cancer TME.